» Articles » PMID: 39064199

The Hurdle of Access to Emerging Therapies and Potential Solutions in the Management of Dyslipidemias

Overview
Journal J Clin Med
Specialty General Medicine
Date 2024 Jul 27
PMID 39064199
Authors
Affiliations
Soon will be listed here.
Abstract

This review explores the many barriers to accessing lipid-lowering therapies (LLTs) for the prevention and management of atherosclerotic cardiovascular disease (ASCVD). Geographical, knowledge, and regulatory barriers significantly impede access to LLTs, exacerbating disparities in healthcare infrastructure and affordability. We highlight the importance of policy reforms, including pricing regulations and reimbursement policies, for enhancing affordability and streamlining regulatory processes. Innovative funding models, such as value-based pricing and outcome-based payment arrangements, have been recommended to make novel LLTs more accessible. Public health interventions, including community-based programs and telemedicine, can be utilized to reach underserved populations and improve medication adherence. Education and advocacy initiatives led by patient advocacy groups and healthcare providers play a crucial role in raising awareness and empowering patients. Despite the barriers to access, novel LLTs present a big opportunity to reduce the burden of ASCVD, emphasizing the need for collaborative efforts among policymakers, healthcare providers, industry stakeholders, and patient advocacy groups to address these barriers to improve access to LLTs globally.

Citing Articles

Unequal access: the prohibitive costs of new drugs in low- and middle-income countries.

Pettifor J, Saloojee H Nat Rev Nephrol. 2025; .

PMID: 40087511 DOI: 10.1038/s41581-025-00948-z.


An overview of persistent chylomicronemia: much more than meets the eye.

Larouche M, Watts G, Ballantyne C, Gaudet D Curr Opin Endocrinol Diabetes Obes. 2025; 32(2):75-88.

PMID: 39927417 PMC: 11872273. DOI: 10.1097/MED.0000000000000903.


Therapeutic Inertia in Dyslipidemia Management for Secondary Cardiovascular Prevention: Results from the Italian ITACARE-P Network.

Faggiano A, Gualeni A, Barbieri L, Mureddu G, Venturini E, Giallauria F J Clin Med. 2025; 14(2).

PMID: 39860503 PMC: 11765577. DOI: 10.3390/jcm14020493.


Learnings from Implementation Strategies to Improve Lipid Management.

Lan N, Chen R, Dwivedi G, Watts G, Nicholls S, Nelson A Curr Cardiol Rep. 2025; 27(1):9.

PMID: 39775142 PMC: 11711772. DOI: 10.1007/s11886-024-02174-8.

References
1.
Zhai Y, Zhu W, Cai Y, Sun D, Zhao J . Clinical- and cost-effectiveness of telemedicine in type 2 diabetes mellitus: a systematic review and meta-analysis. Medicine (Baltimore). 2014; 93(28):e312. PMC: 4603080. DOI: 10.1097/MD.0000000000000312. View

2.
Mohamed F, Mansfield B, Raal F . Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol. J Clin Med. 2023; 12(15). PMC: 10419884. DOI: 10.3390/jcm12155082. View

3.
Blais J, Wei Y, Knapp M, Wong I, Wei L, Chan E . Trends in PCSK9 inhibitor utilization in the United States, Europe, and other countries: An analysis of international sales data. Am Heart J. 2022; 248:13-20. DOI: 10.1016/j.ahj.2022.02.008. View

4.
Sarnak D, Squires D, Kuzmak G, Bishop S . Paying for Prescription Drugs Around the World: Why Is the U.S. an Outlier?. Issue Brief (Commonw Fund). 2017; 2017:1-14. View

5.
Navar A, Taylor B, Mulder H, Fievitz E, Monda K, Fievitz A . Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy. JAMA Cardiol. 2017; 2(11):1217-1225. PMC: 5963012. DOI: 10.1001/jamacardio.2017.3451. View